Introduction {#Sec1}
============

Osteoporosis is a metabolic bone disease characterized by a chronic excess of bone resorption relative to bone formation, leading to progressive bone loss, deterioration of bone microarchitecture, and increased risk of fracture \[[@CR1]\].

Bone formation and resorption are tightly coordinated during the remodeling cycle. Osteocytes exhibit a mechanosensory capacity and are major regulators of bone remodeling \[[@CR2]\]. Osteoclast-mediated bone resorption releases growth factors from the bone matrix \[[@CR3], [@CR4]\] that increase osteoblast progenitor number, recruitment, differentiation, and activity. In addition, osteoclasts regulate osteoblasts directly via cell-cell contact \[[@CR3], [@CR5]\] and by secreting additional factors \[[@CR6]\] that increase osteoblast number and/or activity. Osteoclast number and activity are regulated by receptor activator of nuclear factor kappa-B ligand (RANKL), a membrane-bound protein produced by neighboring osteocytes and osteoblasts \[[@CR7]\]. Thus, the products of osteoclast activity play a key role in the complex interactive regulation of bone remodeling.

With the exception of parathyroid hormone (PTH) and its analogs, all agents currently used in the treatment of osteoporosis, such as bisphosphonates, selective estrogen receptor modulators, and the anti-RANKL antibody, act primarily by decreasing osteoclast-mediated bone resorption \[[@CR8]\], allowing osteoblasts to increase bone mass by filling in the remodeling space \[[@CR9], [@CR10]\]. Furthermore, slower bone remodeling allows increased bone mineralization, at least for some agents, and leads to a reduction in cortical porosity \[[@CR9]--[@CR12]\]. However, inhibition of osteoclast activity also leads to a secondary reduction in bone formation \[[@CR8], [@CR13]\], limiting the ultimate increase in bone mass.

The mechanism of osteoclast-mediated bone resorption is well characterized \[[@CR7]\]. Osteoclasts attach to the bone surface and secrete hydrogen ions and proteolytic enzymes into the remodeling space. The acidic environment dissolves bone mineral and exposes bone matrix proteins. Cathepsin K (CatK) is the primary osteoclast-produced protease involved in the degradation of type I collagen and other bone matrix proteins \[[@CR14]\]; its pH optimum is in the range of the acidic remodeling space.

Congenital absence of CatK in humans results in pycnodysostosis, a rare autosomal recessive osteochondrodysplasia. This disease is characterized not only by high bone mass but also increased risk of fractures and bone deformities \[[@CR15]\]. Importantly, the increased fragility and bone deformities are not present in heterozygotes \[[@CR15]\]. Targeted disruption of the CatK gene in mice produced a high bone mass phenotype \[[@CR16]\] while overexpression of CatK increased bone turnover and decreased trabecular bone volume \[[@CR17]\].

The effect of CatK inhibition has been studied in estrogen-deficient non-human primates and rabbits. In these studies, CatK inhibitors significantly reduced bone resorption while relatively preserving bone formation, resulting in both increased BMD and bone strength, in contrast to congenital absence of CatK \[[@CR16]\]. CatK inhibition decreased the removal of bone matrix protein but did not reduce osteoclast number or affect other osteoclast activities, such as the production of osteoblast-stimulating factors \[[@CR16]\].

Odanacatib (ODN, MK-0822) is a selective, orally administered CatK inhibitor. Unlike basic CatK inhibitors, ODN is neutral, so it does not accumulate in the acidic environment of lysosomes, which could lead to off-target inhibition of other cathepsins \[[@CR18], [@CR19]\]. ODN is metabolized by CYP3A4, has an apparent terminal half-life of approximately 40 to 80 h \[[@CR20], [@CR21]\], and its absorption is not impaired by food intake \[[@CR20], [@CR21]\].

A phase IIb dose-ranging trial and its extensions have demonstrated progressive dose-dependent increases in BMD in postmenopausal women with low BMD \[[@CR22]--[@CR24]\]. ODN substantially reduced biochemical markers of bone resorption. However, markers of bone formation decreased to a lesser degree than was previously observed with other anti-resorptive treatments and returned towards baseline within 2 years, on continued treatment \[[@CR22]--[@CR24]\]. Histomorphometry of bone biopsies from participants in the phase IIb study indicated that osteoclast number was maintained \[[@CR22]\], confirming preclinical results \[[@CR16]\]. Lack of reduction of serum TRAP5b levels with ODN treatment in the phase IIb trial confirmed osteoclast viability. Discontinuation of ODN treatment resulted in increased bone turnover and reduction in BMD, which returned to baseline within 1 to 2 years \[[@CR23]\]. Based on BMD data after 12 months from the phase IIb trial, ODN 50 mg once weekly was selected as the dosing regimen for the phase III trial \[[@CR22]\].

A prospective study was designed to assess the anti-fracture efficacy and safety of ODN in postmenopausal women with osteoporosis. This report describes the design of this study and presents the key baseline characteristics of its participants.

Study design {#Sec2}
============

Overview of study design {#Sec3}
------------------------

The study, odanacatib Protocol 18, was designed by the sponsor, Merck & Co. Inc., Whitehouse Station, NJ, USA, in collaboration with a Scientific Advisory Committee (SAC) that provided input on the clinical development program.

The study was planned as a multinational, randomized, double-blind, event-driven placebo-controlled trial of approximately 5 years duration and was approved by governing ethical review committees (ERCs) and institutional review boards (IRBs). Provision was made for early termination of the study if criteria for reduction of fracture risk versus placebo were met in prespecified interim analyses (see "[Statistical methods](#Sec22){ref-type="sec"}").

Study participants were women at least 65 years of age and postmenopausal for at least 5 years, who were osteoporosis treatment-naïve or had been exposed to minimal prior osteoporosis treatment. Two categories of participants were eligible (Table [1](#Tab1){ref-type="table"}):Table 1Inclusion criteria and exclusion criteriaInclusion criteria Participant: 1) Is a woman at least 65 years of age 2) Meets one of the following criteria:CriterionFemoral neck or total hip\
BMDFemoral neck and total hip\
BMDPrior vertebral\
fracture^1^Suitable candidate for available osteoporosis\
therapyA≤−1.5≥−4.01YesB≤−2.5≥−4.00YesC≤−1.5No restriction≥1NoD≤−2.5No restriction0No 3) May not be a suitable candidate for commercially available osteoporosis therapy, e.g., due to contraindication, established intolerance, physician's judgment, or participant's unwillingness 4) Has at least one hip that is evaluable by DXA 5) Postmenopausal for at least 5 years 6) Understands the study procedures, alternative treatments available, and voluntarily agrees to participate by giving written informed consent 7) Is ambulatory 8) Is able to read, understand, and complete questionnaires and diariesExclusion criteria Participant: 1) Has chosen treatment with agents demonstrated to reduce the risk of hip fracture 2) Has prior fragility hip fracture and is a suitable candidate for osteoporosis therapy (i.e., bisphosphonates, strontium ranelate, or PTH) 3) Has experienced a clinical fragility fracture (including a clinical vertebral fracture) within the prior 24 months 4) Had more than one prior vertebral fracture, as defined in inclusion criterion 2 above and is a suitable candidate for osteoporosis therapy 5) Has evidence of a metabolic bone disorder other than osteoporosis 6) Has a history of renal stones and serum calcium, serum 25-hydroxyvitamin D, and serum PTH are not all within normal limits. Serum 25-hydroxyvitamin D levels below 20 ng/mL (50 nmol/L) were considered abnormal 7) Has active parathyroid disease 8) Has a history of thyroid disease not adequately controlled by medication 9) Has serum creatinine \>1.6 mg/dL and is considered to have severe renal insufficiency defined as calculated creatinine clearance ≤29 mL/min^2^ 10) Has received treatment with an agent that has an effect on bone including  Bisphosphonates   • Use of any oral bisphosphonate in the 6 months prior to screening   • Use of any oral bisphosphonate for more than 3 months within the prior 2 years   • Lifetime use of more than 6 months total; any lifetime use of IV zoledronate^3^  Within the prior 12 months, use of   • PTH (1--34 or 1--84)  Within the prior 6 months, use of   • Estrogen with or without progestin   • Raloxifene or other SERM, tibolone or an aromatase inhibitor   • Subcutaneous calcitonin^4^  Within the prior 6 months, use for more than 2 weeks of   • Systemic glucocorticoids (≥5 mg/day of prednisone or equivalent)   • Cyclosporin  Within the prior 3 months, use of   • Activated vitamin D (e.g., alphacalcidol)  At any time, use of   • Any anabolic steroid   • Fluoride treatment at a dose greater than 1 mg/day for more than 2 weeks   • Growth hormone   • Any cathepsin K inhibitor   • RANK ligand inhibitor   • Strontium-containing products   • Protease inhibitors for HIV treatment  Current use   • Chemotherapy or heparin   • Vitamin A \>10,000 IU daily   • Vitamin D supplement \>1200 IU daily and is unwilling to limit vitamin D supplement   • Anti-seizure medication and indices of calcium metabolism are *not* within normal limits   • Systemically administered azole antifungals 11) Has a daily calcium intake of \<1200 mg and is unwilling to take study-prescribed calcium supplements 12) Has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that might confound the results of the study or interfere with the participant's participation for the full duration of the study 13) Has a history of malignancy ≤5 years prior to signing informed consent 14) Is \>80 years old and has a history of recurrent falls (≥2 falls in 1 year) 15) Is currently participating in a study with an investigational compound or device 16) Is a user of recreational or illicit drugs or has a recent history (within the last year) of drug or alcohol abuse or dependence 17) Demonstrates hepatic dysfunction defined as\
  Elevation in aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>3 × upper limit of normal (ULN) *and*\
  Elevation in total bilirubin \>2 × upper limit of normal (ULN) 18) Is considered to be at excessive risk of incident fracture according to local Ethics Committee and/or local regulatory agency^1^Defined as anterior, mid, or posterior height loss of \>20 %^2^Using the Cockcroft-Gault formula for creatinine clearance^3^One dose of IV pamidronate or IV ibandronate more than 1 year prior to screening is allowed^4^Use of intranasal calcitonin either prior to or during the study is permittedWomen with a prior radiographic vertebral fracture were required to have a BMD T-score ≤−1.5 at either the femoral neck (FN) or total hip (TH).Those without a prior vertebral fracture were required to have a BMD T-score ≤−2.5 at the FN or TH, using the NHANES III 1998 database (reference values are those for Caucasian young adult women).

In either category, women with prior hip fractures at any time or clinical fragility fractures within the prior 2 years or whose BMD T-score was \<−4.0 at either the FN or TH were excluded to minimize individual participant risk, unless they were unable or unwilling to use available osteoporosis treatments.

This trial was designed to test the hypotheses that treatment with ODN 50 mg once weekly reduces the risk of radiographically detected vertebral, clinical hip, and clinical non-vertebral fractures (all primary end points) in postmenopausal women with osteoporosis. Secondary end points included the incidence of clinical vertebral fractures; change in height; BMD at the TH, FN, trochanter, lumbar spine (LS), 1/3 radius; biochemical markers of bone formation and resorption; and safety and tolerability, including bone histology.

Participants were randomized in a 1:1 ratio to take either ODN 50 mg or matching placebo once weekly, without regard to food or physical position. They were given 5600 international units (IU) of vitamin D~3~ weekly and calcium supplements as needed to ensure a total daily calcium intake of approximately 1200 mg. A dietary calcium questionnaire was administered at intake and at yearly intervals during the trial. Following screening and randomization visits, study visits in the clinic were scheduled every 3 months in the first year of the study and every 6 months thereafter. Telephone contact alternated with clinic visits every 3 months after the first year.

Rationale for study design {#Sec4}
--------------------------

This trial was designed with primary fracture end points, consistent with regulatory requirements for new drugs for the treatment of postmenopausal osteoporosis. It employed a placebo control group, consistent with previous and current registration trials of drugs for that indication. This approach has been the subject of extensive discussion \[[@CR25]\], including a US FDA Advisory Committee Meeting \[[@CR26]\] which provided a frame of reference for recent trial design. Placebo-controlled pivotal trials in osteoporosis were considered acceptable, provided that appropriate limits are placed on the severity of disease in those individuals who could otherwise be treated with available medication. Background treatment with adequate calcium and vitamin D~3~ intake for all participants was also regarded as an important consideration. Limits regarding the range of acceptable BMD and fractures prior to study entry as well as monitoring for excessive on-study bone density decreases have been generally consistent in more recently completed \[[@CR27]\] and ongoing \[[@CR28], [@CR29]\] phase III trials.

Accordingly, the present study excluded participants at relatively high risk for fracture, using specific criteria based on BMD and prior fracture history, and employed safeguards to protect participant safety. The trial was overseen by an external data monitoring committee (DMC) that periodically reviewed unblinded safety data. BMD was measured yearly and identified participants with excessive bone loss (EBL) (predefined as \>7 % from baseline at any time at the LS or TH). If the decrease was confirmed, the participant was then discontinued from study medication and treated conventionally. Adverse events of interest were referred for adjudication by panels of experts with relevant scientific expertise (see section on "[Adverse event reporting and adjudication](#Sec15){ref-type="sec"}").

The study was powered to detect a significant effect of ODN to reduce the risk of hip fractures. Because of the safety criteria at enrollment, the baseline individual hip fracture risk in the study population was limited. Hence, the sample size estimate was about twice that of the largest osteoporosis trial. The event-driven design of the study allowed for some uncertainty in the estimate of the rate at which participants would experience fracture events.

Recruitment, follow-up, and assessments {#Sec5}
=======================================

Recruitment {#Sec6}
-----------

Informed consent was obtained from all study participants before any study procedure was performed. It was required that a qualified physician discuss alternative treatment options with each participant. At the request of a regulatory agency, participant enrollment was conducted in two phases to allow expansion of the safety experience for ODN before the entire study was enrolled.

The first phase (the lead cohort) randomized 1499 participants between November 2007 and March 2008. After 9 months of treatment, the lead cohort safety data were evaluated by the DMC (see below for details), which recommended that the enrollment of the remainder of the participants (the main cohort) could commence. The enrollment of 15,214 participants in the main cohort occurred from January to November 2009 (Fig. [1](#Fig1){ref-type="fig"}). Thus, a total of 16,713 women were recruited at 387 investigational sites in 40 countries.Fig. 1CONSORT Diagram. The *asterisk* indicates 642 randomized participants were excluded from all analyses due to the following reasons: allocation of duplicate allocation numbers (*n* = 3), took no study medication (*n* = 156), or because their study site was closed and excluded from all efficacy and safety data analyses (*n* = 483). The primary all-patients-as-treated analysis will be based on 16,071 participants, of whom 1373 were in the lead cohort. The *dagger* indicates 245 of the 8256 patients were found to be ineligible because they had experienced excessive bone loss detected at the transitional visit

At one investigative site, sponsor inspections identified issues that materially affected data integrity. The sponsor determined that these findings warranted exclusion of that site's data from the primary efficacy and safety analyses and informed the US FDA. (All data, including those excluded from the primary analyses, are to be provided in regulatory submissions). Data from 483 participants were affected, including 111 in the lead cohort. An additional 159 participants were excluded from the analysis because they never took study medication (*N* = 156) or because they had been assigned duplicate allocation numbers (*N* = 3). Thus, the number of evaluable participants was 16,071, including 1373 in the lead cohort.

Randomization and stratification {#Sec7}
--------------------------------

Randomization was performed by a computer-generated allocation schedule using an interactive voice recognition system (IVRS), which randomly assigned each participant to ODN or placebo. Participants were assigned to one of two strata, according to vertebral fracture status. Participants without prior vertebral fracture were assigned to the no-prior-vertebral-fracture stratum. At least two thirds of the participants in the no-prior-fracture stratum were required to be at least 70 years of age. Participants with a prior vertebral fracture were assigned to the prior-vertebral fracture stratum. IVRS was used to keep track of enrollment and the number of participants randomized into each stratum and to close a stratum as needed. IVRS was also available for emergency unblinding if this were required for an individual participant's safety.

Blinding {#Sec8}
--------

Study participants, investigators and their staff, and sponsor's personnel were blinded to treatment allocation. Only the DMC and support statistical personnel (see below) had access to unblinded data. Selected adverse events (AEs) and changes in selected laboratory results were provided to the FDA in an unblinded fashion, while maintaining the blind for study participants, investigators, and other sponsor personnel.

Assessments {#Sec9}
-----------

Prior to randomization, a medical history, including assessment of concomitant medications, physical examination, BMD measurements by dual-energy X-ray absorptiometry (DXA), lateral spine radiographs for vertebral fracture assessment, laboratory assessments, and review of inclusion and exclusion criteria were performed. Follow-up assessments were conducted as follows: limited physical examination including vital signs and laboratory assessment every 3 months during the first year, and then every 6 months. Drug accounting and AE assessments were performed at every visit. Lateral spine radiographs were performed at baseline, month 6, month 12, and every 12 months thereafter. BMD was measured at baseline and yearly thereafter. Height was assessed using a calibrated stadiometer at baseline and yearly.

Radiographic vertebral fracture assessment {#Sec10}
------------------------------------------

Spine radiographs were evaluated at a central site (Synarc, Newark, CA, USA). Screening spine radiographs were evaluated for the presence or absence of a vertebral fracture using the Genant semi-quantitative scale \[[@CR30]\]. Only vertebral fractures in the region T4 to L4 were counted. Participants with Genant grade 1--3 deformities (mild, moderate, or severe) were included in the stratum with prior vertebral fracture.

Follow-up radiographs were evaluated to detect incident (new or worsening) vertebral fractures, first using the Genant semi-quantitative method and upon detection of a fracture, morphometric analysis for confirmation.

BMD measurements {#Sec11}
----------------

BMD was measured using Lunar, Hologic, or Norland densitometers, at femoral sites (total hip, femoral neck, and trochanter) and the lumbar spine in all participants and at the 1/3 radius and total body (excluding head) in a randomly selected 10 % subset of participants from sites with appropriate equipment. The central DXA assessment site (Synarc, Newark, CA, USA) performed QC assessment of all DXA scanners and analysis of all DXA scans.

Laboratory assessments {#Sec12}
----------------------

Serum chemistry, including serum calcium (total and corrected for serum albumin), phosphate, magnesium, liver function tests, hematology, and urinalysis were performed at baseline and follow-up. Serum 25-hydroxyvitamin D, PTH, and biochemical markers of bone turnover were measured in the same subset of participants who underwent 1/3 radius and total body DXA measurements as described above. The following bone turnover markers were measured by Synarc Labs (Lyon, France) on specimens obtained in the fasting state: urinary N-telopeptides of type I collagen (NTx, VITROS ECL/ECIQ, Ortho Clinical Diagnostics, Rochester NY, USA), serum C-telopeptides of type I collagen (CTx, Elecsys-CrossLaps/serum ECL, Roche Diagnostics, Mannheim Germany), serum procollagen type 1 N-terminal propeptide (P1NP, Elecsys/serum ECL kit, Roche Diagnostics, Mannheim Germany), and serum bone-specific alkaline phosphatase (BSAP, Access Ostase, Beckman Coulter, Brea, CA, USA). Fasting urine and serum specimens were archived from each participant at all visits.

Bone biopsy {#Sec13}
-----------

Transilial bone biopsy was an optional procedure in participants who provided a separate consent. A total of 341 biopsies were obtained from 272 participants. Forty biopsies were obtained at baseline and 301 after 12, 24, or 36 months. Double-fluorochrome labeling with either tetracycline or demeclocycline was used to assess bone formation. The biopsy specimens were analyzed at the Osteoporosis Research Center, Creighton University, Omaha, NE, USA using histomorphometric and micro-CT techniques \[[@CR31]\]. Biopsy examiners were blinded to participant identity, treatment allocation and time-point. Histomorphometric variables were measured, calculated, and expressed according to the guidelines of the American Society of Bone and Mineral research (ASBMR) Nomenclature Committee \[[@CR32]\].

Clinical fracture end point assessment {#Sec14}
--------------------------------------

Clinical vertebral and non-vertebral fractures were key end points of the study. Therefore, all fractures reported as AEs were adjudicated by a clinical adjudication committee (CAC) of radiologists at the central evaluation site (Synarc, Newark, CA, USA). Based on clinical history and radiographs, the CAC determined whether a fracture was confirmed; its anatomic location and laterality; and whether it was osteoporotic or due to trauma, stress, or other pathology (neoplasm or infection). The adjudication involved a two-round process. A unanimous vote from three CAC members, chosen at random from a panel of four, who reviewed the participant data independently via internet-based software (Virtual Panel System, Parexel International, Waltham, MA, USA), was required to complete the adjudication during the first review. If the vote were not unanimous, then all four CAC members would review the case in a conference (second review) and a three-fourths majority vote was required to confirm the fracture. The CAC could also determine that insufficient data were available to complete the adjudication of a fracture event. Fractures that were possible atypical femoral shaft fracture events were adjudicated according to the ASBMR criteria and were always discussed by four CAC members in a one-round process \[[@CR33], [@CR34]\].

Adverse event reporting and adjudication {#Sec15}
----------------------------------------

At each clinic or telephone visit, participants were queried about interval AEs and the responses recorded. Participants were also instructed to report any serious AEs such as hospitalization to the investigational sites immediately. Changes in laboratory parameters were evaluated by the investigators to determine whether they were clinically significant and reportable as AEs.

Several categories of specific AEs were designated for adjudication by external CAC committees (cardiovascular, cerebrovascular, dental, skin thickening and hardening, delayed fracture union, and serious respiratory events) to confirm their occurrence and specific attributes. These AEs, rationale for their adjudication, data collected for the adjudication, and specific attributes to be adjudicated are summarized in Table [2](#Tab2){ref-type="table"}. These AEs were adjudicated in a two-round process similar to that previously described for fractures. Adjudication of all AEs was managed by a central site (Parexel International, Waltham, MA, USA), which was responsible for collection of all clinical data, electronic distribution to the CAC members, coordination of CAC member conferences, collation of adjudication results, and final data transfer to the sponsor.Table 2Adjudicated adverse eventsAdverse eventRationale for adjudicationData collected for adjudication^1^Attributes adjudicatedMorphea-like skin lesionsReported in phase IIb study of balicatibPhotographs, serology, pathology report, or slides for skin biopsy\
The investigators were provided with specific instructions regarding the evaluation of cutaneous adverse events reported at clinic study visits or telephone visits. Specific questions were asked at each visit, about the appearance and texture of the skin, and relevant additional information obtained. There were provisions for dermatologic assessment and biopsy when appropriate, as well as provision for rheumatologic consultation in instances of new or worsening morpheaConfirm morpheaSystemic sclerosisMonitored as a precaution because of the finding of morphea-like skin lesions in the balicatib trialPhotographs, serology, pathology report, or slides for skin biopsyConfirm systemic sclerosisSerious respiratory infectionDose-related increased incidence in phase IIb study of balicatibChest X-ray, CT scan, spirometry, laboratory tests, culture and sensitivityConfirm that event is primarily respiratory and has an infectious component, determine etiology if possibleOsteonecrosis of the jawReported in participants treated with bisphosphonates and denosumab, although a causal relationship has not been conclusively establishedRadiographsConfirm diagnosis and location, assess for risk factorsAtypical femoral shaft fracture^2^Femur shaft fractures with less common (i.e., atypical) radiographic and clinical features have been reported with both bisphosphonates and denosumab. Standardized review of both femur fracture radiographs and clinical history is required to identify the major and minor features of atypical fractures according to ASBMR Task Force criteria \[[@CR33], [@CR34]\]RadiographsConfirm diagnosisDelayed fracture union^2^Rule out adverse effect for a drug used for the treatment of osteoporosis and fracture preventionRadiographsConfirm diagnosis, assess for risk factorsAtrial fibrillation^3^Reports of an excess incidence of serious atrial fibrillation in placebo-controlled trials of zoledronic acidECG, cardiac diagnostic procedure reportsConfirm diagnosis, assess for risk factorsCardiovascular events^3^Observation of plaque stabilization in an animal model of accelerated atherosclerosis with cathepsin K deletion. Test hypothesis of a potential beneficial effect with cathepsin K inhibition in reducing the incidence of thrombotic cardiovascular and cerebrovascular eventsECG, cardiac diagnostic procedure reports, cardiac enzymesConfirm diagnosis (myocardial infarction, unstable angina, cardiac thrombus), assess for risk factorsCerebrovascular eventsECG, cardiac diagnostic procedure reports, cerebrovascular imagingConfirm diagnosis of stroke, determine etiology (thrombotic vs. hemorrhagic) if possible, assess for risk factors^1^Clinical notes, hospital notes, and admission and discharge summary that describe the diagnosis, treatment, and clinical course of the event are collected for all cases submitted for adjudication. For radiographs, ECG, pathology slides, original, or copies are preferred, but report or summary of results by qualified medical personnel are acceptable^2^Same CAC as for fractures^3^Same CAC for atrial fibrillation and cardiovascular events

Discontinuation criteria {#Sec16}
------------------------

Participants were discontinued from blinded study drug if the investigator considered that the risk outweighed the benefit of continued participation on blinded therapy for an individual participant. Additionally, participants were discontinued from blinded study drug if they experienced excessive bone loss, as described above; initiated treatment with a strong CYP3A4 inducer (e.g., carbamazepine, phenytoin, rifampin, St. John's wort) for longer than 6 months; commenced treatment with other drugs for osteoporosis; or had persistent elevations in serum transaminases or bilirubin. The sponsor provided alendronate 70 mg OW to patients who were discontinued from study drug, although other treatment options were not prohibited. Participants were followed for outcome and safety monitoring through the end of the base trial even if blinded study therapy was discontinued.

Data monitoring committee {#Sec17}
-------------------------

The ODN clinical development program, including this fracture outcome study, was monitored by a DMC, which consisted of seven experts not involved in the conduct of the study, including six physicians, five of whom were experts in osteoporosis with subspecialty expertise in endocrinology, rheumatology, geriatrics, and epidemiology; a dermatologist; and a non-physician statistician. The DMC was supported by a statistician and statistical programmer from the sponsor. Only the DMC and their support statistical personnel had access to unblinded data from the trial, with the exception that safety data were provided to the FDA in an unblinded fashion as described above. Since September 2007, the DMC has met at intervals of approximately 4 months to review safety data from the ODN program, including data from this trial, and to make recommendations on the conduct of the trials. The DMC was also responsible for the review of the two planned interim efficacy analyses and had the option of recommending to the sponsor to terminate the study early due to futility or due to robust efficacy and a favorable benefit-risk profile of the drug.

Ancillary studies {#Sec18}
=================

Population pharmacokinetics study {#Sec19}
---------------------------------

Three specimens were collected from each participant in the lead cohort for the measurement of plasma ODN levels to confirm findings from phase I. Information was collected with regard to timing of the collection and last dose of ODN and characteristics of the meal prior to last dose.

Special imaging sub-study {#Sec20}
-------------------------

A sub-study of 164 participants investigated the effect of ODN on volumetric BMD of the hip and spine and, specifically, on the trabecular and cortical components at each site, using quantitative computed tomography (QCT, instruments from GE Medical Systems, Phillips, Siemens, and Toshiba). High-resolution peripheral QCT (Scanco Xtreme CT) was employed to investigate the effect of ODN on bone microarchitecture at the distal radius and distal tibia in some of these participants. Imaging procedures were performed yearly, and all participants in this study had biochemical markers of bone turnover measured at these time-points. Only participants in this sub-study were asked to consent to optional bone biopsies at baseline and 12 months.

Sarcopenia end point sub-study {#Sec21}
------------------------------

This was an exploratory sub-study of 556 participants designed to identify molecular signatures of sarcopenia using DNA and RNA biomarkers in the blood and to examine changes in appendicular lean body mass, measured by total body DXA, and physical function, measured by the Short Physical Performance Battery (SPPB).

Participation in the special imaging and sarcopenia sub-studies was optional and involved separate consent forms from those used for the main study.

Statistical methods {#Sec22}
===================

Data analysis {#Sec23}
-------------

The primary end points of the study were the first morphometrically confirmed vertebral fracture per participant, first osteoporotic clinical hip fracture confirmed by adjudication, and first osteoporotic clinical non-vertebral fracture confirmed by adjudication. There was a hierarchical order from morphometric vertebral fractures (the first primary end point) to the other two end points; there was no order set between hip and non-vertebral fractures.

The all-patients-as-treated population (*n* = 16,071) was used for safety analyses and included all participants who took at least one dose of study medication and had at least one follow-up visit with the exclusions noted above. Treatment groups were compared using the Miettinen and Nurminen method \[[@CR35]\], adjusted for differential follow-up period, for prespecified sets of AEs of clinical relevance.

The full-analysis population was used for efficacy analyses. With the exclusions noted above in "[Recruitment](#Sec6){ref-type="sec"}," it included all randomized participants who took at least one dose of study medication regardless of protocol violation, adherence to study medication, or early discontinuation from the study and had at least one follow-up efficacy assessment. The follow-up period was from randomization to study termination. The number of patients included in the efficacy analyses varied according to the number and timing of observations for each end point.

Morphometrically confirmed vertebral fracture data were evaluated with a generalized linear model for binary data with the complementary log-log transformation of the probability of an event up to the time-point. Clinical hip and non-vertebral fracture data were analyzed by time-to-event methods using Kaplan-Meier estimates and a Cox proportional hazards model.

A step-down procedure \[[@CR36]\] controlled for increased false positive error risk due to multiple primary end points, in the order of (1) morphometric vertebral fractures and (2) clinical hip and clinical non-vertebral fractures. Significance of the morphometric vertebral fracture primary end point was required before testing the other two primary end points. The Hochberg procedure was used to control for the multiplicity of fracture end points \[[@CR37]\].

For BMD end points, treatments were compared using a longitudinal model with terms for treatment, stratum, geographic region, and treatment-time interaction on the percent change from baseline. Log-transformed fractional change from baseline in biochemical markers was analyzed using the same model as BMD. Yearly rate of height loss was analyzed using a longitudinal model. Testing for secondary end points was performed only if significance for the first primary end point (morphometric vertebral fractures) was obtained. For the purpose of addressing the issue of multiplicity adjustment, three groups were considered: (1) BMD measures, (2) biochemical markers of bone resorption, and (3) clinical vertebral fractures and height. Hochberg multiplicity adjustment procedure was used within each of three groups. No adjustment for multiplicity between the three groups was applied.

Sample size considerations {#Sec24}
--------------------------

To provide at least 90 % statistical power to demonstrate a risk reduction of vertebral fracture by 50 %, hip fracture by 35 %, or non-vertebral fracture by 20 %, the estimated required numbers of participants with these fractures were 114, 237, and 824, respectively. Sample size estimates were based on the fracture incidence in the alendronate Fracture Intervention Trial (FIT) and assumed that approximately 25 % of participants would have a prior radiographic vertebral fracture \[[@CR38]\]. The estimated enrollment requirement was based on hip fracture projections, since these events are least frequent. On this basis, randomization of approximately 16,000 participants was planned.

Interim analyses {#Sec25}
----------------

Two interim analyses were planned to be conducted, when approximately 70 and 85 % of the targeted 237 participants had experienced an osteoporotic hip fracture event. To adjust for multiplicity, an alpha spending function was used for the interim and final analyses, such that *p* values of approximately 0.007, 0.018, and 0.046 were required for the first and second interim and final analyses, respectively.

Planned subgroup analyses {#Sec26}
-------------------------

Prespecified subgroup analyses for the primary efficacy end points included age (\<70 and ≥70 years), race, prior radiographic vertebral fracture, baseline BMD T-score tertiles, baseline biochemical bone turnover marker tertiles, geographic region, baseline renal function, bisphosphonate intolerance, vitamin D status, BMI tertiles, and participation in the lead or main cohort. Subgroup analyses including age, race, bisphosphonate intolerance, and ability or willingness to be treated with available osteoporosis therapies were conducted for the following safety end points: combined clinical as well as combined laboratory AEs and skin disorders and dental disorders reported by investigators as AEs.

Participant baseline characteristics {#Sec27}
====================================

The numbers of participants screened and enrolled are shown in Fig. [1](#Fig1){ref-type="fig"} and their geographical distribution in Table [3](#Tab3){ref-type="table"}. Baseline characteristics are shown in Table [4](#Tab4){ref-type="table"}. The average age of the study population was 72.8 years, 56.5 % of the participants were Caucasian, and the average number of years since menopause was 25.3. Baseline vertebral fractures were identified in 46.5 % of subjects.Table 3Geographic distribution of investigational sites and participantsGeographic regionNumber (%) of investigational sitesNumber (%) of participants randomizedFracture trial Asia110 (28.4)3151 (18.9) Latin America62 (16.0)5442 (32.6) Europe/US/others215 (55.6)8120 (48.6) Total38716,713^1^Special imaging sub-study South Africa3 (30.0)61 (37.2) Europe/US/others7 (70.0)103 (62.8) Total10164Sarcopenia end point sub-study Asia3 (8.8)73 (13.1) Latin America8 (23.5)263 (47.3) Europe/US/others23 (67.6)220 (39.6) Total34556Bone biopsy Asia2 (7.7)6 (2.2) Latin America9 (34.6)51 (18.6) Europe/US/others15 (57.7)215 (79.2) Total26272^1^Three randomized participants were subsequently excluded due to assignment of duplicate allocation numbersTable 4Participant baseline characteristicsEvaluable participants\
(*n* = 16,071)Age (years), mean (SD)72.8 (5.3) \>70 years old, n (%)11,004 (68.5)Race, *n* (%) Caucasian9085 (56.5) Asian2832 (17.6) Multiracial3706 (23.1) Black/African American261 (1.6) Native American185 (1.2) Pacific Islander2 (0.001)BMD T-score, mean (SD) Lumbar spine−2.7 (1.2) Total hip−2.4 (0.7) Femoral neck−2.7 (0.5) Trochanter−2.3 (0.8)Bone turnover markers, mean (SD)^1^ uNTX/Cr (nmol/mmol Cr)47.4 (37.4) sCTX (ng/mL)0.44 (0.22) sBSAP (ng/mL)15.78 (6.50) sP1NP (ng/mL)58.62 (28.81)Clinical fracture history since menopause, *n* (%) Any5552 (34.5) Hip224 (1.4) Spine1439 (9.0) Other4407 (27.4)Years since menopause, mean (SD)25.3 (7.7)Prior radiographically assessed vertebral fracture, *n* (%)^2^7446 (46.4) Mild fracture (Genant grade 1)4414 (59.3) Moderate fracture (Genant grade 2)1858 (25.0) Severe fracture (Genant grade 3)1174 (15.8)Unreliable or missing data36^1^Measured in 10 % subset of participants^2^Grade of fracture was determined based on the worst grade per participant over all available scans up to 7 days after first study dose

Extension study {#Sec28}
===============

In recent years, questions have arisen about the benefits and risks of long-term treatment with osteoporosis medications \[[@CR39]\]. At the initiation of the current trial, it was anticipated that up to 5 years of blinded therapy might be required to evaluate its end points, and this duration was specified in the protocol and participant consent forms that were approved by ERCs and IRBs. Provision was made for early termination of the study if significant reductions in fracture risk were demonstrated in either preplanned interim analysis. In order to ensure collection of long-term data, an extension study was planned in which study participants would continue in a blinded fashion on their randomized treatment until they reached the originally anticipated total of 5 years, after which participants would transition to open-label ODN.

Current status {#Sec29}
==============

On July 11, 2012, the sponsor announced the decision to terminate the base study early based on the DMC recommendation following its review of the first interim analysis. That analysis was performed after approximately 70 % of the target hip fracture events (158 participants with an incident osteoporotic hip fracture) had occurred. The DMC based its recommendation on the observation of robust efficacy and a favorable benefit/risk profile of ODN relative to placebo. The DMC also recommended that additional safety data be obtained in the previously planned blinded extension study. Following this recommendation, study participants attended a final base study visit and, if eligible, were asked to consent to enter the extension study. The base study was closed out between August and November, 2012, and will form the basis for the primary comparative efficacy and safety analyses.

There were important differences between the base and extension studies in study design and conduct. In the base study, all participants who discontinued study medication were allowed to remain in the trial and be followed unless they withdrew consent. However, participants who were no longer taking study medication at the time of their final base study visit were not eligible to enter the extension. Of 16,713 women initially randomized in the base study, 8256 entered the extension study. Of the approximately 8000 women who did not enter the extension, most were ineligible because they had not completed the base study on therapy or because the investigational site did not participate in this phase of the trial. A total of 1281 women experienced excessive bone loss during the base study. Most of them discontinued prior to entering the extension. However, 245 women were excluded shortly after entering the extension because of excessive bone loss detected at the transitional visit.

The loss of nearly half the original participants created a substantial likelihood that the extension population would differ materially from the original trial population. Participants who experienced excessive bone loss during the base study were discontinued from study drug and were therefore ineligible to enter the study extension. It would be expected that a greater number of participants from the placebo arm were discontinued due to excessive bone loss. Thus, although it was blinded, the extension cannot be presumed to have maintained the randomization.

As osteoporosis requires long-term treatment, extension studies of active treatment, with or without a withdrawal arm, have become customary. Prior trials have not generally extended the randomized placebo phase beyond the primary end point. In the report of the 10-year extended phase III alendronate studies, the authors used the expected effect of aging on fracture rates in the original placebo group in order to provide context for interpretation of the rates observed on active treatment in the latter years \[[@CR40]\]. A more sophisticated approach, taking more variables into account, was subsequently developed and validated using data from the alendronate FIT trial \[[@CR41]\]. This "virtual twin" model has been used in the analyses of data from the long-term extension of the denosumab phase III trial for which a placebo comparison was no longer available \[[@CR42]\]. A similar model will be developed from the placebo group in the ODN base study. This may provide useful information about expected fracture rates and other efficacy and safety results for a virtual long-term placebo group with characteristics matching the active treatment population.

Summary {#Sec30}
=======

Inhibition of cathepsin K is an attractive pharmacological approach with therapeutic potential in osteoporosis. Preclinical and initial clinical data provided a strong rationale for the use of ODN in the treatment of osteoporosis, and the phase IIb trial identified 50 mg once weekly as a dose regimen that is effective on BMD end points. The ODN phase III fracture trial was designed to rigorously investigate the efficacy and safety of this selective CatK inhibitor in the treatment of osteoporosis in postmenopausal women.

This placebo-controlled study excluded participants who were at excessively high individual risk of fracture and included safeguards to ensure participant safety. In addition to fractures, the study evaluated multiple end points that not only provide information about ODN but may also help expand our knowledge of osteoporosis. An interim analysis demonstrated sufficiently robust anti-fracture efficacy and favorable benefit-risk profile to warrant early termination of the base study. The blinded extension study enrolled more than 8000 continuing participants and will provide additional data concerning the longer-term safety and efficacy of ODN.
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